Trial intelligence / Profile preview

Benzoic acid add-on study in treatment-resistant schizophrenia

ACTRN12615000460505Phase 2Terminated

Sponsor
University of Otago
Start
Mar 2016
Modality
Small Molecules
Countries
1
01

Overview

Phase 2, open-label, single-arm trial of Benzoic acid in schizophrenia, sponsored by University of Otago. Primary endpoints: Positive and Negative Symptom Scale, Scale for the Assessment of Negative Symptoms and 1 more. Started Mar 2016; status: terminated.

02

Drugs

Benzoic acid
03

Conditions

schizophrenia

Beyond the preview

Go deeper on ACTRN12615000460505.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ACTRN12615000460505.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call